Holoxan (ifosfamide) 2,000 mg, for intravenous injection, Baxter, Germany Order Holoxan (ifosfamide) 2,000 mg, for intravenous injection, Baxter, Germany. Medicine delivery from Europe within 4-5 days with storage conditions maintained. Payment on delivery. Contact +380996042415.

Interchangeable drugs with the same active ingredient:

• Vero-Ifosfamid
• Wizfamid
• Ifolem
• Ifos
• Ifosfamid
• Ifosfamide-Health
• Holoxan 1 G
• Holoxan 2 G
• Holoxan 500

Indications

Testicular tumors

• As part of combination chemotherapy for patients with advanced tumors of stage II-IV according to the TNM classification (international classification of malignant tumors) (Semina and non-Seminoma), which responded insufficiently or did not respond at all to primary chemotherapy.

Cervical carcinoma (carcinoma of the cervix)

• Palliative combination chemotherapy with cisplatin / ifosfamide (without additional combination drugs) for stage IV B cervical carcinoma according to the classification of the International Federation of Obstetrics and Gynecology (FIGO) (if radical treatment with surgery or radiation therapy is not possible), as an alternative to palliative radiation therapy.

Breast cancer

• As palliative therapy for advanced resistant or recurrent breast cancer.

Non-small cell bronchial carcinoma

• As monotherapy or as part of combination chemotherapy in patients with inoperable or metastatic tumors.

Small cell bronchial carcinoma

• As part of combination chemotherapy.

Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma)

• As monotherapy or as part of combination chemotherapy, rhabdomyosarcoma or osteosarcoma when standard treatment is ineffective.
• As monotherapy or as part of combination chemotherapy for other soft tissue sarcomas when surgical and radiation therapy is ineffective.

Ewing's sarcoma

• As part of combination chemotherapy when primary cytostatic therapy is ineffective.

Non-Hodgkin's lymphoma

• As part of combination chemotherapy for patients with high-grade non-Hodgkin's lymphoma, responded insufficiently or not at all to primary therapy. As part of combination therapy for patients with recurrent tumors.

Hodgkin's disease

• For the treatment of patients with Hodgkin's disease, primarily with a progressive course or at the beginning of relapse (duration of complete remission less than one year), after failure of primary chemotherapy or radiochemotherapy as part of combination chemotherapy regimens, such as the Protocol MINE.